DCAL2024-10-012024-12-31 DCAL2024-10-012024-12-31 DCAL2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member DCAL2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member DCAL2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member DCAL2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member DCAL2024-12-31 DCAL2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DCAL2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member DCAL2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss03Member DCAL2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DCAL2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member DCAL2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss03Member DCAL2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member DCAL2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member DCAL2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member DCAL2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 540701 DCAL NA Dishman Carbogen Amcis Limited Equity 2024-04-01 2025-03-31 2025-02-12 2025-02-08 INR Crores Third quarter 15:00:00 17:30:00 2025-02-12 2025-02-12 Not applicable Single segment Contract Research and Manufacturing Services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, disinfectants etc. 2024-10-01 2024-12-31 Unaudited Consolidated 6823400000.00 56300000.00 6879700000.00 1615800000.00 0.00 -627500000.00 3320800000.00 487800000.00 719700000.00 1113000000.00 6629600000.00 250100000.00 20400000.00 270500000.00 266400000.00 -42200000.00 224200000.00 0.00 46300000.00 0.00 0.00 0.00 0.00 46300000.00 -1733300000.00 -1687000000.00 46300000.00 0.00 -1687000000.00 0.00 313600000.00 2 0.30 0.30 0.00 0.00 0.30 0.30 0.00 0.02 0.03 1. The Financial results (standalone and consolidated) have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 12th February, 2025. 2. Consolidated financial results comprise the results of the parent Company, Dishman Carbogen Amcis Limited and its subsidiaries (together referred as “the Group”) viz. Dishman CARBOGEN AMCIS (Europe) Ltd., Dishman USA Inc., Dishman International Trading (Shanghai) Co. Ltd, CARBOGEN AMCIS Holdings AG., Switzerland; CARBOGEN AMCIS (Shanghai) Co. Ltd.,; CARBOGEN AMCIS BV, Carbogen Amcis Ltd., U.K., CARBOGEN AMCIS AG (“CGAM AG”), Switzerland, CARBOGEN AMCIS SAS, Dishman Carbogen Amcis (Japan) Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd.,; Dishman Biotech Ltd.; CARBOGEN AMICS Specialities AG.; CARBOGEN AMICS Innovations AG.; DISHMAN CARBOGEN AMCIS AG.; CARBOGEN AMCIS Real Estate, Dishman Medicare Limited (formerly known as Visible Investment Limited) and Dishman Carbogen AMCIS Technology AG. Note: for full notes to FR, refer Quick Result Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 19951600000.00 137100000.00 20088700000.00 4388100000.00 0.00 -830700000.00 9686300000.00 1173400000.00 2146500000.00 3545400000.00 20109000000.00 -20300000.00 -63600000.00 -83900000.00 485700000.00 -171100000.00 314600000.00 0.00 -398500000.00 0.00 0.00 0.00 0.00 -398500000.00 -195900000.00 -594400000.00 -398500000.00 0.00 -594400000.00 0.00 313600000.00 2 -2.54 -2.54 0.00 0.00 -2.54 -2.54 0.00 0.02 0.03 Other Expenditure 1107700000.00 SaaS IT project cost 5300000.00 Other Expenditure 3522800000.00 SaaS IT project cost 22600000.00 Remeasurement gain/(losses) on defined benefit plans -2900000.00 Income Tax effect 800000.00 Changes in fair value of FVTOCI equity instruments 2500000.00 Remeasurement gain/(losses) on defined benefit plans -867900000.00 Income Tax effect 112300000.00 Changes in fair value of FVTOCI equity instruments 3000000.00 400000.00 -752600000.00 800000.00 1000000.00 Movement in foreign currency translation reserve -1640600000.00 Foreign exchange fluctuations in respect of cash flow hedge -65200000.00 Movement in foreign currency translation reserve 683500000.00 Foreign exchange fluctuations in respect of cash flow hedge -195800000.00 -1705800000.00 487700000.00 27100000.00 -70000000.00